Skip to main content

RESMED INC

For the period ended Jun 30, 2024. Filed Aug 9, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Aug 9, 2024

RMD$234.11-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. Selected Financial Data

The following table summarizes certain selected consolidated financial data for, and as of the end of, each of the fiscal years in the five-year period ended June 30, 2024. The data set forth below should be read together with Item 7 of Part II of this report, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Item 8 of Part II of this report, “Consolidated Financial Statements and Supplementary Data”, and related notes included elsewhere in this report. The consolidated statement of income data for the years ended June 30, 2024, 2023 and 2022 and the consolidated balance sheet data as of June 30, 2024 and 2023 are derived from our audited consolidated financial statements included elsewhere in this report. The consolidated statement of income data for the years ended June 30, 2021 and 2020 and the consolidated balance sheet data as of June 30, 2022, 2021 and 2020 are derived from our audited consolidated financial

-47-

PART IIItem 6

statements not included in this report. Historical results do not necessarily indicate the results to be expected in the future, and the results for the years presented should not be considered to indicate our future results of operations.

Consolidated Statement of Income DataYears Ended June 30,
(In thousands, except per share data):20242023202220212020
Net revenue$4,685,297$4,222,993$3,578,127$3,196,825$2,957,013
Cost of sales (exclusive of amortization shown separately below)1,997,0311,836,9351,514,1661,312,5981,189,624
Amortization of acquired intangible assets32,96330,39639,65045,12749,603
Total cost of sales2,029,9941,867,3311,553,8161,357,7251,239,227
Gross profit2,655,3032,355,6622,024,3111,839,1001,717,786
Selling, general and administrative expenses917,136874,003737,508670,387676,689
Research and development expenses307,525287,642253,575225,284201,946
Amortization of acquired intangible assets46,52142,02031,07831,07830,092
Restructuring expenses64,2289,177—8,673—
Litigation settlement expenses————(600)
Acquisition related expenses—10,9491,864——
Total operating expenses1,335,4101,223,7911,024,025935,422908,127
Income from operations1,319,8931,131,8711,000,286903,678809,659
Other income:
Interest expense, net(45,708)(47,379)(22,312)(23,627)(39,356)
Loss attributable to equity method investments(1,848)(7,265)(8,486)(11,205)(25,058)
Gain on insurance recoveries—20,227———
Other, net(7,539)4,210(9,005)14,816(12,157)
Total other income (loss), net(55,095)(30,207)(39,803)(20,016)(76,571)
Income before income taxes1,264,7981,101,664960,483883,662733,088
Income taxes243,847204,108181,046409,157111,414
Net income$1,020,951$897,556$779,437$474,505$621,674
Basic earnings per share$6.94$6.12$5.34$3.27$4.31
Diluted earnings per share$6.92$6.09$5.30$3.24$4.27
Dividends per share$1.92$1.76$1.68$1.56$1.56
Weighted average:
Basic shares outstanding147,021146,765146,066145,313144,338
Diluted shares outstanding147,550147,455147,043146,451145,652
As of June 30,
Consolidated Balance Sheet Data (In thousands):20242023202220212020
Working capital$1,447,064$1,609,297$1,242,179$662,991$920,698
Total assets$6,872,394$6,751,708$5,095,853$4,728,125$4,587,376
Long-term debt, less current maturities$697,313$1,431,234$765,325$643,351$1,164,133
Total stockholders’ equity$4,864,043$4,129,903$3,360,751$2,885,679$2,497,027

-48-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.